Samarsh, Vyom Partners, Blue Lotus support expansion plans
Hyderabad’s Sai Parenterals Limited has completed a US$5.82 million (Rs.50 crore) equity investment round by a group of marquee investors for establishing its international footprint as it pursues its vision to become a global pharmaceutical company http://commerce.gov.in.
The company operates five facilities in India, of which some are approved by TGA Australia, GCC, SAPRA and WHO GMP, supporting a growing presence in both domestic and key international markets.
Samarsh Capital, Vyom Partners, and funds associated with Blue Lotus Capital led the fundraising round.
Anil Karusala, Managing Director of Sai Parenterals, said on 9 July, “This equity infusion will allow us to acquire high-potential international assets and intellectual property in regulated markets, expand our product portfolio and geographical presence, and enhance our manufacturing capabilities.
“We are working diligently to build a world-class pharmaceutical company that adheres to the highest global standards and practices. We are honoured by the confidence of such professional investors in our company’s strategy and future.”
Harikrishnan S, Managing Partner of Blue Lotus Capital, elaborated, “Our second round of investment reflects our strong conviction in Sai Parenterals’ science-driven culture and scalable manufacturing platform. By partnering with a formidable player in sterile injectables, we aim to accelerate affordable, high-quality healthcare solutions for global markets while delivering sustained value to the investors.”
Sandeep Shenoy, Managing Partner of Samarsh Capital, added, “Our investment in Sai Parenterals reflects our confidence in its solid fundamentals, scalable model, and potential to achieve strong growth in the global pharmaceutical sector. Under the visionary leadership of Anil, we expect Sai Parenterals to emerge as a leader in its segment.”
Prashant Khanchandani of Vyom Partners, noted, “Sai Parenterals’ leadership has demonstrated a future-ready approach by building a capital-efficient and scalable business. Their success in integrating acquisitions and subsequently expanding internationally in the formulations and CDMO segments is commendable.”
Sai Parenterals Limited is an Indian pharmaceutical company with a proven track record in the formulations segment. The company operates across the pharmaceutical value chain, including research & development (R&D), manufacturing, regulatory compliance, marketing, and exports https://pharma-dept.gov.in/.
With two strategic business verticals, Branded Export Formulations and Contract Development & Manufacturing Organization (CDMO) Services, Sai Parenterals focuses on delivering value-added drug formulations. The company has built a diverse portfolio across dosage forms, including injectables, oral solids and liquids, and topical preparations. Fiinews.com
